12 completed, 10 unknown, 6 recruiting, 5 terminated. 13 Phase 3, 11 Phase 2, 4 Phase 1, 2 Phase 4, 1 Early Phase 1.
Follow Primary Immune Thrombocytopenia: new trials by email Literature Review of Primary Immune Thrombocytopenia trials Research Report on Primary Immune Thrombocytopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Amgen | 126 | 2026-08-21 | 2026-09-17 |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-26 | 2026-10-15 | |
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients low dose group, high dose group, Placebo group - Primary Immune Thrombocytopenia | Phase 2 | Recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 60 | 2026-06-11 | 2026-09-09 |
| A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment Primary Immune Thrombocytopenia | Recruiting | Novartis Pharmaceuticals | 100 | 2025-12-08 | 2026-10-01 | |
| A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults TQB3473 Tablets - Primary Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 320 | 2025-08-01 | 2025-07-24 |
| A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia TQB3473 Tablets, TQB3473 Placebo - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 199 | 2025-04-30 | 2025-05-20 |
| Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. Eltrombopag 25 MG, Prednisolone - Primary Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | Renata PLC | 100 | 2025-02-07 | 2025-02-18 |
| Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP) No intervention - Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia | Completed | Sanofi | 97 | 2025-01-13 | 2026-01-26 | |
| Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP corticosteroids combined with immunoglobulin and romiplostim - Primary Immune Thrombocytopenia | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 36 | 2024-11-20 | 2025-01-22 |
| Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) CM313 injection, placebo - Primary Immune Thrombocytopenia | Phase 2 | Active not recruiting | Keymed Biosciences Co.Ltd | 62 | 2024-11-11 | 2025-04-23 |
| Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010 Primary Immune Thrombocytopenia | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 157 | 2024-09-01 | 2024-06-20 | |
| A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP Dexamethasone Combined with romiplostim N01, Dexamethasone monotherapy - Primary Immune Thrombocytopenia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 129 | 2024-06-01 | 2024-10-26 |
| The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) HMPL-523 - Immune Thrombocytopenia, Blood Platelet Disorder | Phase 1 | Withdrawn | Hutchmed | 2024-04-02 | 2025-09-16 | |
| The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects STSA-1301 subcutaneous injection, Placebo - Primary Immune Thrombocytopenia | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 36 | 2023-11-16 | 2024-08-12 |
| Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) data collection - Primary Immune Thrombocytopenia | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 500 | 2023-11-01 | 2026-02-11 | |
| Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study Fostamatinib - Primary Immune Thrombocytopenia | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 50 | 2023-03-01 | 2023-10-17 | |
| A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 152 | 2023-02-02 | 2026-08-21 |
| Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia romiplostim plus dexamethasone, Dexamethasone - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 129 | 2022-12-02 | 2025-06-17 |
| Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults Intravenous immunoglobulin (IVIG), 10% solution for infusion - Primary Immune Thrombocytopenia | Phase 3 | Completed | Biopharma Plasma LLC | 32 | 2022-07-26 | 2024-09-23 |
| Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients 2.5mg/d Hetrombopag - Primary Immune Thrombocytopenia | Phase 4 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 69 | 2022-05-01 | 2022-04-05 |
Showing 20 of 41. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (41) · Anemia, Aplastic (1) · Autoimmune Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bronchiolitis Obliterans Syndrome (1) · Hematologic Diseases (1) · Hemorrhage (1) · Hemorrhagic Disorders (1) · Immune System Diseases (1) · Pathologic Processes (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Purpura (1) · Purpura, Thrombocytopenic (1) · Sjogren's Syndrome (1)
Cytopenia (41) · Hemic and Lymphatic Diseases (41) · Pathological Conditions, Signs and Symptoms (41) · Signs and Symptoms (41) · Autoimmune Diseases (40) · Blood Coagulation Disorders (40) · Blood Platelet Disorders (40) · Hematologic Diseases (40) · Hemorrhage (40) · Hemorrhagic Disorders (40) · Immune System Diseases (40) · Pathologic Processes (40) · Purpura (40) · Purpura, Thrombocytopenic (40) · Skin Manifestations (40)
efgartigimod alfa (3) · eltrombopag (3) · ianalumab (3) · romiplostim (3) · rozanolixizumab (3) · hetrombopag (2) · Acetylcysteine (1) · Atorvastatin (1) · Data Collection (1) · Dexamethasone (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Population Groups (1) · Prednisolone (1) · Solutions (1)
argenx (5) · Novartis Pharmaceuticals (4) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · UCB Biopharma SRL (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Pfizer (2) · Amgen (1) · Assiut University (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Biopharma Plasma LLC (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hangzhou Sumgen Biotech Co., Ltd. (1) · Henri Mondor University Hospital (1)
China (19) · United States (15) · United Kingdom (13) · Spain (12) · Germany (9) · Italy (9) · Poland (9) · Japan (8) · Ukraine (8) · Bulgaria (7) · France (7) · Hungary (7) · Russia (7) · Georgia (6) · Belgium (5)
Adrian Newland (1) · Charlotte Bradbury (1) · Enrique Cervantes-Perez, MD, MSc (1) · Heba A Abdel-Hafeez, Professor (1) · Hend M Moness, professor (1) · Heng Mei, PhD (1) · Hu Yu, M.D., Ph.D (1) · Lei Zhang (1) · Lei Zhang, MD (1)
PMID 15661401, PMID 19005182, PMID 19446149, PMID 19846889, PMID 22054810, PMID 22409309, PMID 2279341, PMID 23556122, PMID 24802773, PMID 29270980, PMID 30344993, PMID 31821591, PMID 34452956, PMID 34528239, PMID 37778358, PMID 38130645, PMID 38546375, PMID 39552477, PMID 41363800, PMID 41943179, PMID 41950473
2019 (6), 2016 (1), 2018 (1), 2023 (1)